Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,893 active trials21 approved drugs383 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00851136 | A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | completed | Phase 1 | 9 | Genentech, Inc.INDUSTRY | 0 | Dec 13, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 |
| clinicaltrials |
| NCT02857270 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | completed | Phase 1 | 210 | Eli Lilly and CompanyINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT01220999 | A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 19 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05536362 | Propofol With Clonidine and Ketamine Throughout Colon Cancer Surgery | completed | Phase 1 | 60 | EgymedicalpediaINDUSTRY | 1 | Oct 26, 2022 | clinicaltrials |
| NCT01975831 | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | completed | Phase 1 | 104 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT00199797 | Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 20 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 10, 2022 | clinicaltrials |
| NCT00291486 | Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 19 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02713373 | Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 45 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT05368805 | Fruquintinib DDI Study With P-gp and BCRP Substrates | completed | Phase 1 | 32 | HutchmedINDUSTRY | 1 | Oct 6, 2022 | clinicaltrials |
| NCT02310464 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | completed | Phase 1 | 25 | OBI Pharma, IncINDUSTRY | 1 | Oct 3, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT01064375 | Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer(El-porCEA) | completed | Phase 1 / Phase 2 | 16 | Maria LiljeforsOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT02602327 | Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases | completed | Phase 1 | 21 | University of California, San FranciscoOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05476341 | A Phase I Clinical Trial of Bevacizumab Injection | completed | Phase 1 | 98 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03274804 | Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC(PICCASSO) | completed | Phase 1 | 20 | University Hospital HeidelbergOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT03332498 | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | completed | Phase 1 / Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT02833753 | Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI | completed | Phase 1 | 14 | University of Massachusetts, WorcesterOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT02935309 | Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT03391232 | PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)(OBERTO) | completed | Phase 1 / Phase 2 | 11 | Treos Bio ZrtINDUSTRY | 2 | May 26, 2022 | clinicaltrials |
| NCT00416351 | Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT01113736 | Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy(AlloMem) | completed | Phase 1 | 10 | University Hospitals Cleveland Medical CenterOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04088786 | Phase I Trial HIPEC With Nal-irinotecan | completed | Phase 1 | 18 | Stony Brook UniversityOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT01154335 | Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 | 18 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT03974594 | Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients | completed | Phase 1 | 64 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02641873 | A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 4 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02249650 | To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.(TSB-9-W1) | completed | Phase 1 | 21 | Taiwan Sunpan Biotechnology Development Co., Ltd.OTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | completed | Phase 1 | 283 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 29, 2022 | clinicaltrials |
| NCT03254394 | Lidocaine for Oxaliplatin-induced Neuropathy | completed | Phase 1 / Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03454620 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | completed | Phase 1 / Phase 2 | 53 | Green Cross CorporationINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03985072 | Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor | completed | Phase 1 | 67 | Andes BiotechnologiesINDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02248805 | Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma | completed | Phase 1 | 95 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02636036 | Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors(SPICE) | completed | Phase 1 | 51 | Akamis BioINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT05110118 | Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects | completed | Phase 1 | 112 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Nov 5, 2021 | clinicaltrials |
| NCT03100045 | Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)(ART-AIN) | completed | Phase 1 | 18 | Johns Hopkins UniversityOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000764 | Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection. | completed | Phase 1 | 98 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03152370 | Preoperative Radiotherapy and E7046 in Rectum Cancer(PRAER 1) | completed | Phase 1 | 29 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 3 | Oct 4, 2021 | clinicaltrials |
| NCT02777710 | Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers(MEDIPLEX) | completed | Phase 1 | 48 | Centre Leon BerardOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03564912 | Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC | completed | Phase 1 / Phase 2 | 160 | Zhejiang UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01270698 | Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer | completed | Phase 1 | 26 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04607291 | Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening | completed | Phase 1 | 183 | Roswell Park Cancer InstituteOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT00844233 | Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer(PARAGON-II) | completed | Phase 1 / Phase 2 | 40 | Boston Scientific CorporationINDUSTRY | 3 | Jul 21, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 13, 2022source: clinicaltrials